Innate Pharmaceuticals AB
47 Umestan Företagspark
28 articles with Innate Pharmaceuticals AB
Innate Pharma Presents New Data on Next-Generation NK Cell Engager Platform at FOCIS 2021 Annual Meeting
Innate Pharma SA announced it will present the latest preclinical data from its next- generation, proprietary, multi-specific NK cell engager platform known as ANKET™ at the Federation of Clinical Immunology Societies meeting.
New Lacutamab Data From Tellomak Trial to be Showcased in Oral Presentation at Upcoming 16th International Conference on Malignant LymphomaFirst clinical data of mycosis fungoides presented from the TELLOMAK trial
Innate Pharma SA announced that preliminary mycosis fungoides data from the Phase 2 TELLOMAK trial evaluating lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody in development for T-cell lymphomas, will be presented during an oral presentation at the virtual 16th International Conference on Malignant Lymphoma taking place from June 18-22, 2021.
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities General Regulation, Innate Pharma SA releases its total number of shares outstanding as well as its voting rights as of May 1, 2021
Innate Pharma SA has published the convening notice to the Bulletin des Annonces Légales Obligatoires for its Annual General Meeting of Shareholders, which will take place virtually at 11:00 a.m. CEST on May 28, 2021.
Lacutamab TELLOMAK trial progresses as KIR3DL2-expressing mycosis fungoides cohort advances to Stage 2 after positive early signal
Innate Pharma SA, announced that the Company will hold a conference call on Thursday, May 11, 2021 at 3 p.m. CEST / 9 a.m. ET, to give an update on business progress during the first quarter of 2021.
Innate Pharma Files Its 2020 Universal Registration Document (Document D’enregistrement Universel) and 2020 Annual Report on Form 20-F
Innate Pharma SA announced the filing of its 2020 Universal Registration Document for the year ending December 31, 2020 with the French market authority “Autorité des Marchés Financiers” on April 27, 2021.
Innate Pharma SA will hold its Annual General Meeting of Shareholders at 11:00 a.m. CET on May 28, 2021.
Lacutamab received PRIME designation from the European Medicines Agency in Sezary Syndrome; clinical development program advances in mycosis fungoides and peripheral T-cell lymphoma
Innate Pharma SA, announced that the Company will hold a conference call on Thursday, March 18, 2021 at 2 p.m. CET / 9 a.m. ET, following the release of its financial results for the full year ending December 31, 2020.
Innate Pharma SA announced that members of its senior management team are scheduled to participate in the following upcoming virtual investor conference
TELLOMAK trial progresses as cohort 2 of KIR3DL2-expressing mycosis fungoides patients advances to Stage 2 earlier than anticipated
Innate Pharma to Host Key Opinion Leader Discussion on the Potential Role of Lacutamab Across T-Cell LymphomasVirtual event to take place at 2:00 p.m. CET / 8:00 a.m. ET on Tuesday, February 9, 2021
Innate Pharma SA announced that it will host a virtual key opinion leader discussion focused on the potential role of its lead investigational drug candidate, lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody in development for T-cell lymphomas.
IPH6101/SAR443579 is an NKp46-based NK cell engager (NKCE) that uses Innate’s proprietary multispecific antibody format
All corporate information, such as the Company’s financial statements and corporate presentations, is available on https://investors.innate-pharma.com.
Lacutamab granted PRIME designation inSézary Syndrome by the European Medicines Agency
Innate Pharma Receives Prime Designation From the European Medicines Agency for Lacutamab in Sézary Syndrome Priority
Priority Medicines (PRIME) designation supports the potential for lacutamab to benefit Sézary Syndrome patients in need of new treatment options
Innate Pharma SA, announced that members of its senior management team are scheduled to participate in the following upcoming virtual investor conferences.
INTERLINK-1 represents first Phase 3 study examining IO approach in R/M SCCHN patients who have been treatedwith a platinum-based therapy and PD-(L)1 inhibitor
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities General Regulation, Innate Pharma SA releases its total number of shares outstanding as well as its voting rights as at October 1, 2020:.